Displaying results 37 - 48 of 79
Metabolism, Alcohol & Toxicity

The role of Gremlin-1 in pathogenesis and treatment in rodent and human NASH

Webcasts
View
Metabolism, Alcohol & Toxicity

NAFLD is associated with significantly higher risk of cardiovascular outcomes in the absence of fibrosis - a prospective UK Bi...

Webcasts
View
Metabolism, Alcohol & Toxicity

Proteomics and spatial transcriptomics show that ADAMTSL2 is a promising biomarker in NAFLD with significant fibrosis

Webcasts
View
Metabolism, Alcohol & Toxicity

Exploring the impact of the genetic PNPLA3 I148M variant on primary human hepatic stellate cells by using healthy and diseased...

Webcasts
View
Metabolism, Alcohol & Toxicity

Double-blinded randomized controlled trial assessing the effect of consecutive fecal microbiota transplantation (FMT) on hepat...

Webcasts
View
Metabolism, Alcohol & Toxicity

Sexual dimorphism: the overlooked obvious?

Webcasts
View
Metabolism, Alcohol & Toxicity

Personalized medicine in 2032 – how will it look like? (Complete Session)

Webcasts
View
Metabolism, Alcohol & Toxicity

Gut microbiota as a target for personalized NAFLD interventions

Webcasts
View
Metabolism, Alcohol & Toxicity

Gene silencing by siRNA treatment

Webcasts
View
Metabolism, Alcohol & Toxicity

Biomarkers for personalized NAFLD medicine – thinking outside the box

Webcasts
View
Metabolism, Alcohol & Toxicity

Panel discussion

Webcasts
View
Metabolism, Alcohol & Toxicity

How do pharmacological treatments of comorbidities affect NAFLD – case-based discussion (Complete Session)

Webcasts
View
Displaying results 37 - 48 of 79